← Evidence map

ArticleNutrition & diabetes2014

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin.

B Haas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

46 papers cite it

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 25365416